Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. Winter 2013;15(4):194-201.
doi: 10.7224/1537-2073.2012-034.

Treatment Discontinuation and Disease Progression With Injectable Disease-Modifying Therapies: Findings From the North American Research Committee on Multiple Sclerosis Database

Affiliations
Free PMC article

Treatment Discontinuation and Disease Progression With Injectable Disease-Modifying Therapies: Findings From the North American Research Committee on Multiple Sclerosis Database

Robert J Fox et al. Int J MS Care. .
Free PMC article

Abstract

Injectable first-line disease-modifying therapies (DMTs) for multiple sclerosis (MS) are generally prescribed for continuous use. Accordingly, the various factors that influence patient persistence with treatment and that can lead some patients to switch medications or discontinue treatment may affect clinical outcomes. Using data from the North American Research Committee on Multiple Sclerosis (NARCOMS) database, this study evaluated participants' reasons for discontinuation of injectable DMTs as well as the relationship between staying on therapy and sustained patient-reported disease progression and annualized relapse rates. Participants selected their reason(s) for discontinuation from among 16 possible options covering the categories of efficacy, safety, tolerability, and burden, with multiple responses permitted. Both unadjusted data and data adjusted for baseline age, disease duration, disability, and sex were evaluated. Discontinuation profiles varied among DMTs. Participants on intramuscular interferon beta-1a (IM IFNβ-1a) and glatiramer acetate (GA) reported the fewest discontinuations based on safety concerns, although GA was associated with reports of higher burden and lower efficacy than other therapies. Difficulties with tolerability were more often reported as a reason for discontinuing subcutaneous (SC) IFNβ-1a than as a reason for discontinuing IM IFNβ-1a, GA, or SC IFNβ-1b. In the persistent therapy cohort, less patient-reported disability progression was reported with IM IFNβ-1a treatment than with SC IFNβ-1a, IFNβ-1b, or GA. These findings have relevance to clinical decision making and medication compliance in MS patient care.

Figures

Figure 1.
Figure 1.
Time to PDDS-defined sustained progression A, IM IFNβ-1a (black) versus SC IFNβ-1b and SC IFNβ-1a (combined data set, gray). B, IM IFNβ-1a (black) versus SC GA (gray). C, SC IFNβ-1b and SC IFNβ-1a (black) versus SC GA (gray). Data were analyzed using Cox proportional hazards regression with propensity score adjustments to reduce selection bias in treatment comparisons. CI, confidence interval; GA, glatiramer acetate; HR, hazard ratio; IFNβ, interferon beta; IM, intramuscular; PDDS, Patient-Determined Disease Steps; SC, subcutaneous.

Similar articles

See all similar articles

Cited by 9 articles

See all "Cited by" articles

LinkOut - more resources

Feedback